Primary cancer prevention for cancers with no known infectious etiology: Time for a new paradigm. Read more about Primary cancer prevention for cancers with no known infectious etiology: Time for a new paradigm.
Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women. Read more about Effectiveness of 'catch-up' human papillomavirus vaccination to prevent cervical neoplasia in immunosuppressed and non-immunosuppressed women.
Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men. Read more about Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.
Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives. Read more about Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives.
In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection. Read more about In vivo and in vitro immunogenicity of novel MHC class I presented epitopes to confer protective immunity against chronic HTLV-1 infection.
Immunogenicity and safety of the 9-valent HPV vaccine in men. Read more about Immunogenicity and safety of the 9-valent HPV vaccine in men.
Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica. Read more about Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.
Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Read more about Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Read more about Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males.
Updating the natural history of human papillomavirus and anogenital cancers. Read more about Updating the natural history of human papillomavirus and anogenital cancers.
